Table 1.
Number of conflicts per patient group submission.
Table 2.
Examples of patient group positive, neutral and negative views about a drug-indication.
Table 3.
Distribution of patient group views about drug-indications under consideration*.
Table 4.
Comparison of views of patient groups with recommendations from Common Drug Review and panCanadian Oncology Drug Review*, †.
Table 5.
Subsequent entry biologics (SEB)–distribution of views of patient groups.
Table 6.
Patient group response to preliminary recommendation from panCanadian Oncology Drug Review.